Document Detail

N-acetylcysteine improves the clinical conditions of mustard gas-exposed patients with normal pulmonary function test.
MedLine Citation:
PMID:  18801028     Owner:  NLM     Status:  MEDLINE    
Administration of N-acetylcysteine may be effective in diseases caused by oxidative-antioxidative imbalance. We aimed to determine the effect administration for 4 months of N-acetylcysteine (1200 mg daily) on sulfur mustard-induced bronchiolitis obliterans in patients with normal pulmonary function test. In a double-blind clinical trial, 144 patients with bronchiolitis obliterans due to sulfur mustard and bronchiolitis obliterans syndrome class 0, randomly entered to group 1 (n = 72, N-acetylcysteine) and group 2 (n = 72, placebo). The changes in dyspnoea, wake-up dyspnoea, cough and sputum were measured after 4 months using a 'delta value' (i.e. symptom score after 4 months--symptom score before the trial). Spirometric findings were measured at the beginning of the trial, 2 months later and 4 months later. Dyspnoea (delta value: -0.78 (0.61), P < 0.001), wake-up dyspnoea (delta value: -0.57 (0.64), P < 0.001), and cough (delta value: -0.86 (0.63), P < 0.001) improved after 4 months of N-acetylcysteine administration compared to the control group. N-acetylcysteine reduced sputum from 76.9% (n = 40) of cases before the trial to 9.6% (n = 5) of cases after the trial. Spirometric components were significantly improved in N-acetylcysteine group compared to the placebo group: FEV1 (P < 0.0001), FVC (P = 0.014) and FEV1/FVC (P = 0.003). A 4-month trial with 1200 mg oral N-acetylcysteine per day can be used for treating bronchitis, but is also effective in treating bronchiolitis. It also prevents sulfur mustard-induced oxidative stress, and can be used in the treatment of sulfur mustard-induced pulmonary disease.
Mostafa Ghanei; Majid Shohrati; Mehrdad Jafari; Soleyman Ghaderi; Farshid Alaeddini; Jafar Aslani
Related Documents :
7960688 - A multicenter, double-blind, randomized controlled study of omeprazole versus ranitidin...
3534198 - Glycine-based oral rehydration solution: reassessment of safety and efficacy.
16741368 - Once daily sublingual immunotherapy without updosing--a new treatment schedule.
25288 - Long-term hypnotic efficacy and safety of triazolam and flurazepam.
20546528 - Intravenous immunoglobulin preparation type: association with outcomes for patients wit...
24497538 - Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2008-09-17
Journal Detail:
Title:  Basic & clinical pharmacology & toxicology     Volume:  103     ISSN:  1742-7843     ISO Abbreviation:  Basic Clin. Pharmacol. Toxicol.     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-10-24     Completed Date:  2008-12-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101208422     Medline TA:  Basic Clin Pharmacol Toxicol     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  428-32     Citation Subset:  IM    
Research Center of Chemical Injuries, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetylcysteine / pharmacology,  therapeutic use*
Antioxidants / pharmacology,  therapeutic use*
Bronchiolitis Obliterans / chemically induced,  drug therapy*,  physiopathology
Chemical Warfare Agents / toxicity*
Double-Blind Method
Follow-Up Studies
Forced Expiratory Volume / drug effects
Middle Aged
Mustard Gas / toxicity*
Oxidative Stress / drug effects
Respiratory Function Tests
Sputum / drug effects
Time Factors
Vital Capacity / drug effects
Reg. No./Substance:
0/Antioxidants; 0/Chemical Warfare Agents; 505-60-2/Mustard Gas; 616-91-1/Acetylcysteine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mechanism of paroxetine-induced cell death in renal tubular cells.
Next Document:  Cardioprotective effects of Nigella sativa oil on cyclosporine A-induced cardiotoxicity in rats.